Randomised study: effects of the 5‐HT₄ receptor agonist felcisetrag vs placebo on gut transit in patients with gastroparesis

Abstract

I.V. felcisetrag significantly accelerated gastric, small bowel and colonic transit in patients with gastroparesis, and should be further evaluated for short-term treatment of gastric and intestinal motility disorders. ClinicalTrials.gov #NCT03281577.